A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

NCT03006926 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: lenvatinib
DRUG: pembrolizumab (200 mg)

Sponsor

Eisai Co., Ltd.

Collaborators

[object Object]